[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attr-amyloidosis-wild-type\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attr-amyloidosis-wild-type":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,75,100,126,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100518735","analysis-of-lumbar-spine-stenosis-specimens-for-identification-of-transthyretin-cardiac-amyloidosis-100518735",false,"NCT06034405","Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis","Inclusion Criteria:\n\n1. Clinically indicated spinal decompressive surgery within 20 years prior to enrollment.\n2. Age ≥50 years at the time of the surgery.\n3. Able to understand and sign the informed consent document after the nature of the study has been fully explained.\n\nExclusion Criteria:\n\nThe presence of any of the following excludes eligibility for enrollment in this study:\n\n1. Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA).\n2. Known TTR amyloidosis.\n3. Other reason that would make the subject inappropriate for entry into this study.",true,"ALL","50 Years",{"count":19,"type":20},1663,"ESTIMATED","OBSERVATIONAL","Primary objective:\n\nTo identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.\n\nThe specific aims of this epidemiologic investigation include:\n\n1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis.\n2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.\n\nThe study will also explore the following:\n\n1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining.\n2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry.\n3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H\\&E staining.\n4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).",[24,25,26,27,28,29],"Lumbar Spinal Stenosis","Cardiac Amyloidosis","ATTR Amyloidosis Wild Type","ATTR Gene Mutation","ATTRV122I Amyloidosis","Cardiomyopathy, Hypertrophic","RECRUITING","2026-06-02",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2023-09-19",{"date":38,"type":20},"2028-05",{"name":40,"class":41},"Columbia University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100540547","phase-1-haemodynamic-effects-of-dobutamine-in-patients-with-wild-type-transthyretin-amyloid-cardiomyopathy-attrwt-100540547","NCT06318260","Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)","DobATTR","Inclusion Criteria:\n\n1. ATTRwt, diagnosis confirmed by genetic testing, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and\u002For endomyocardial biopsy.\n2. Treated with loop diuretics.\n3. New York Heart Association class II-IV.\n4. Age ≥ 65 years.\n5. Left ventricular ejection fraction (LVEF) \\\u003C 50 % and\u002For SVI assessed by echocardiography \\\u003C 35 ml\u002Fm2.\n6. Thorough oral and written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Moderate to severe aortic stenosis (participants with aortic sclerosis will not be excluded).\n2. Other significant valvular diseases.\n3. Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction (\\\u003C 4 weeks).\n4. Contraindications to the use of dobutamine: Known allergy to dobutamine or sulfite, phaeochromocytoma or ventricular tachycardia (VT).\n5. End stage renal disease (eGFR of less than 15 mL\u002Fmin\u002F1,73 m2).","65 Years",{"count":51,"type":20},15,"INTERVENTIONAL",[54,55],"PHASE1","PHASE2","The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). The main questions it aims to answer are:\n\n* What are the effects of increasing dosages of dobutamine infusion on cardiac output and filling pressures in patients with symptomatic ATTRwt.\n* Safety of dobutamine infusion in this patient population.\n\nParticipants will receive increasing doses of dobutamine infusion, and the effects on cardiac output and filling pressures will be assessed simultaneously by echocardiography and right heart catheterization.",[26],[59,60,61,62,63,64],"Cardiac amyloidosis","Inotropic","ATTR-CM","Transthyretin amyloid cardiomyopathy","Dobutamine","wild type ATTR","2026-05-27",{"date":67,"type":34},"2026-06-01",{"date":69,"type":34},"2024-04-08",{"date":71,"type":20},"2027-09",{"name":73,"class":41},"Steen Hvitfeldt Poulsen",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":74},"100535434","national-referral-center-study-of-transthyretin-amyloid-cardiomyopathyattr-patients-on-tafamidis-100535434","NCT06251778","NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis","NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis: Real World Prospective Study","NOTE-ATTR","Inclusion Criteria:\n\n* Diagnosis of ATTRwt amyloidosis.\n* 18 years or older;\n* evidence of cardiac involvement at echocardiography or cardiac MRI.\n* No known prior history of atrial fibrillation or major bradyarrhythmia (second degree atrioventricular block, third-degree atrioventricular block, high-grade atrioventricular block or alternating right and left branch block)\n* female patients who are postmenopausal for at least 1 year before the screening visit\n* patients on therapy or candidates for therapy with tafamidis 61 mg\n* voluntary written consent must be given before performance of any study-related procedure not part of standard medical care with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.\n\nExclusion Criteria:\n\n* Non-ATTR amyloidosis;\n* NYHA class III and IV;\n* Pregnant or nursing women;\n* Previous pacemaker implantation;\n* any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with a fully comprehension of the written consent form","18 Years","99 Years",{"count":86,"type":20},200,"All ATTRwt patients on tafamidis 61 mg treatment will be clinically evaluated before treatment initiation and subsequently every six months for the eligibility to continue tafamidis treatment, according to Italian Medicines Agency regulations. C onsidering the significant risk of developing heart rhythm disturbances due to cardiac amyloidosis, especially in transthyretin form (ATTRwt), in routine clinical practice a stricter heart rhythm monitoring is recommended in ATTRwt patients. Moreover, particular attention is usually paid for those who present atrio-ventricular and\u002For intraventricular block at the baseline electrocardiogram. Data about rhythm disturbances and diuretic dose need will be collected during the planned physical examination every six months and the Holter ECG monitoring requested by the physician at the end of every planned clinical evaluation.",[89,90,26],"Amyloidosis","Amyloidosis Cardiac","2026-04-13",{"date":93,"type":34},"2026-04-16",{"date":95,"type":34},"2024-01-26",{"date":97,"type":20},"2027-01-26",{"name":99,"class":41},"Paolo Milani",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100580339","a-multicenter-study-on-atrioventricular-regurgitation-in-transthyretin-amyloid-cardiomyopathy-definition-prevalence-and-prognostic-impact-100580339","NCT06836011","A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.","Definition and Prognosis of Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy - a Prospective International Multicenter Study","Inclusion Criteria:\n\n* Diagnosis of ATTR-CM according to current diagnostic criteria\n* Comprehensive baseline echocardiographic assessment, including (semi-)quantitative mitral and tricuspid regurgitation (MR\u002FTR) parameters, performed within ±6 months of diagnosis\n* Age ≥ 18 years\n* Willingness to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Severe aortic valve disease requiring intervention\n* Inability to provide informed consent or participate in study follow-up",{"count":108,"type":20},600,"The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurgitation severity, tailored to the distinct hemodynamic profile of ATTR-CM. This approach seeks to address the limitations of current regurgitation severity classifications, which do not adequately reflect the unique pathophysiology of a restrictive phenotype as seen in ATTR-CM.",[111,61,26,112,113],"ATTR Amyloidosis With Cardiomyopathy","Mitral Regurgitation","Tricuspid Regurgitation",[61,115,113,112],"ATTR amyloidosis","2025-02-14",{"date":118,"type":34},"2025-02-19",{"date":120,"type":34},"2025-01-01",{"date":122,"type":20},"2026-12-31",{"name":124,"class":41},"Medical University of Vienna",8,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":52,"phases":136,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100554436","eoss-attr-study-ehealth-based-operative-support-system-in-attr-cm-100554436","NCT06499064","EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","Information and Communications Technology (ICT)-based Modeling of Transthyretin-associated Amyloidosis Cardiomyopathies (ATTR-CM) Care: EOSS-ATTR Study (eHealth Based Operative Support System in ATTR-CM)","eOSS-ATTR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* HF diagnosis according to European Society of Cardiology (ESC)\n* Patients with a HF decompensation in the last 12 months\n* Confirmed diagnosis of ATTR-CM (ATTRv or ATTRwt)\n* Written informed consent\n\nExclusion Criteria:\n\n* Age\\\u003C18 years old\n* Participation in another clinical trial\n* Moderate or severe cognitive impairment without a competent caregiver\n* Lack of social support\n* Institutionalized patients\n* Life expectancy less than 1 year (excluding HF)\n* Institutional-based or end-of-life care\n* Serious psychiatric illness\n* Planned cardiac surgery\n* Planned heart transplantation or left ventricular assist device (LVAD) implant\n* Patients in haemodialysis program\n* The patient is unable or unwilling to give the informed consent to participate\n* The patient is considered an unsuitable candidate for this study according to the decision of the local investigator\n* Unstable patients with signs of fluid overload or low cardiac output",{"count":135,"type":20},50,[137],"NA","Unicenter, proof-of-concept, prospective, randomised, controlled, open-label and blinded end-point adjudication trial to assess the effect on patient-reported outcomes measures (PROMs), patient-reported experience measures (PREMs) and clinical events of a mHealth-based comprehensive management program for patients with chronic heart failure (HF) due to transthyretin-associated amyloidosis (ATTR)-cardiomyopathy (CM) by means of remote daily telemonitoring of signs and symptoms and remote structured follow-up using videoconference.",[140,141,26,27],"Heart Failure","Amyloid Cardiomyopathy",[143],"eHealth; mHealth; telemonitoring; ATTR, heart failure","NOT_YET_RECRUITING","2024-10-21",{"date":147,"type":34},"2024-10-23",{"date":149,"type":20},"2024-12-01",{"date":151,"type":20},"2026-03-15",{"name":153,"class":41},"Hospital Universitari de Bellvitge",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":74},"100551306","attr-cardiac-amyloidosis-in-a-selected-population-100551306","NCT06458374","ATTR Cardiac Amyloidosis in a Selected Population","Prevalence and Long Tem Follow Up of ATTR Cardiac Amyloidosis in a Selected Population of Patients Operated on Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Male \\> 50 years\n* Female \\> 60 years\n* operated CTS at Ålesund Hospital\n\nExclusion Criteria:\n\n* not consented\n* do not speak Norwegian\n* secondary cause of CTS as traumatic or rheumatic\n* cannot be followed \\> 5 years due to other medical conditions\n* Cardiac disease at time of operation for CTS",{"count":162,"type":20},180,"Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.",[26,27,165,25],"Carpal Tunnel Syndrome","2024-10-14",{"date":168,"type":34},"2024-10-16",{"date":170,"type":34},"2024-09-01",{"date":172,"type":20},"2039-02-28",{"name":174,"class":175},"Helse Møre og Romsdal HF","OTHER_GOV"]